CVE:AQS Aequus Pharmaceuticals (AQS) Stock Price, News & Analysis C$0.0050 0.00 (-37.50%) As of 04/25/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsInsider TradesBuy This Stock About Aequus Pharmaceuticals Stock (CVE:AQS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aequus Pharmaceuticals alerts:Sign Up Key Stats Today's RangeC$0.01▼C$0.0150-Day RangeC$0.01▼C$0.0152-Week RangeC$0.01▼C$0.04Volume100,000 shsAverage Volume162,442 shsMarket CapitalizationC$663.15 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada. Read More Receive AQS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AQS Stock News HeadlinesAequus Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (AQS)January 22, 2025 | theglobeandmail.comAequus Pharmaceuticals Reports Revenue Growth Amid RestructuringNovember 9, 2024 | markets.businessinsider.comPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.July 11 at 2:00 AM | Paradigm Press (Ad)Aequus Pharmaceuticals Inc. (AQSZF)September 5, 2024 | finance.yahoo.comAequus Pharmaceuticals Inc (AQS)August 3, 2024 | investing.comClosing Bell: Aequus Pharmaceuticals Inc down on Friday (AQS)July 23, 2024 | theglobeandmail.comAequus Pharmaceuticals Full Year 2023 Earnings: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)May 2, 2024 | finance.yahoo.comAQS:CA Aequus Pharmaceuticals Inc.April 19, 2024 | seekingalpha.comSee More Headlines AQS Stock Analysis - Frequently Asked Questions How have AQS shares performed this year? Aequus Pharmaceuticals' stock was trading at C$0.01 at the beginning of the year. Since then, AQS shares have decreased by 50.0% and is now trading at C$0.01. How do I buy shares of Aequus Pharmaceuticals? Shares of AQS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Aequus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aequus Pharmaceuticals investors own include Growlife (PHOT), Unrivaled Brands (TRTC), Acorn Energy (ACFN), Crown Castle (CCI), LiCo Energy Metals (LIC), Marijuana Company of America (MCOA) and Rogers (ROG). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:AQS CIKN/A Webwww.aequuspharma.ca Phone+1-604-3367906FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$2.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,569.60% Return on Assets-178.79% Debt Debt-to-Equity Ratio138.88 Current Ratio0.07 Quick Ratio0.46 Sales & Book Value Annual SalesC$1.17 million Price / Sales0.57 Cash FlowC$0.00 per share Price / Cash Flow5.00 Book ValueC($0.04) per share Price / Book-0.13Miscellaneous Outstanding Shares132,630,000Free FloatN/AMarket CapC$663.15 thousand OptionableNot Optionable Beta-0.02 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (CVE:AQS) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aequus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aequus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.